EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.
AI Generated Analysis | Feedback
- Vertex Pharmaceuticals for eye diseases.
- Like a specialized division of Pfizer, but entirely dedicated to developing medicines for eye conditions.
AI Generated Analysis | Feedback
- DEXYCU®: An intraocular steroid injection approved for the treatment of postoperative inflammation following cataract surgery.
- YUTIQ®: A sustained-release intravitreal implant used to treat chronic non-infectious uveitis affecting the posterior segment of the eye.
- EYP-1901: A sustained-release investigational anti-VEGF therapy in development for the treatment of wet Age-related Macular Degeneration (AMD).
AI Generated Analysis | Feedback
```html
EyePoint Pharmaceuticals (EYPT) sells primarily to other companies.
The company's major customers are pharmaceutical wholesalers. As stated in their financial filings, the primary direct customers for EyePoint Pharmaceuticals are:
- AmerisourceBergen Corporation (ABC)
- Cardinal Health, Inc. (CAH)
- McKesson Corporation (MCK)
```
AI Generated Analysis | Feedback
- Catalent, Inc. (CTLT)
- Fresenius Kabi (Parent: Fresenius SE & Co. KGaA, Symbol: FRE)
- Siegfried Holding AG (SFZN)
AI Generated Analysis | Feedback
Jay S. Duker, M.D. President & CEO and Board Director
Dr. Duker has dedicated over 30 years to ophthalmology, focusing on improving eyesight and preventing blindness through various roles in clinical research, business, and academia. He joined EyePoint in 2020, becoming President & CEO in July 2023, after serving as President and Chief Operating Officer, and Chief Strategic Scientific Officer. He also previously served on EyePoint's Board of Directors from 2016-2020. Dr. Duker founded three successful start-up companies: SurgiSite Boston, the Boston Image Reading Center (BIRC), and Hemera Biosciences. Hemera Biosciences, a gene therapy company, was acquired by Janssen in 2020.
George O. Elston Executive Vice President, Chief Financial Officer
Mr. Elston possesses over 30 years of diverse financial and senior leadership experience within the biopharmaceutical sector. He joined EyePoint in 2019 as Chief Financial Officer and Head of Corporate Development, and was promoted to Executive Vice President in October 2023. Prior to EyePoint, he served as Chief Financial Officer & Head of Corporate Development at Enzyvant Therapeutics, where he contributed to building the precommercial rare disease firm, which was subsequently acquired. He also served as President and Chief Executive Officer at 2X Oncology, Inc., where he developed the company from a spin-out into a multiprogram, clinical-stage organization.
Ramiro Ribeiro, M.D., Ph.D. Chief Medical Officer
Dr. Ribeiro is a retinal specialist who leads EyePoint's Clinical Development, Clinical Operations, and Medical Safety teams. He brings over 15 years of experience spanning clinical practice, academia, and the pharmaceutical industry to his role.
Ron Honig Esq. Chief Legal Officer & Company Secretary
Mr. Honig serves as the Chief Legal Officer and Company Secretary for EyePoint Pharmaceuticals.
Scott Jones, M.A. Chief Commercial Officer
Mr. Jones is responsible for the commercialization of EyePoint's innovative ophthalmic products, leveraging his significant experience in commercializing drugs and devices globally. Before joining EyePoint in 2019, he held roles such as Chief Commercial Officer and Vice President, Business Development, at Notal Vision, and President of QLT Ophthalmics. He also held various senior roles at Novartis Pharmaceuticals.
AI Generated Analysis | Feedback
The development and potential commercialization of gene therapies and other ultra-long-acting therapeutic modalities for chronic retinal diseases, such as wet age-related macular degeneration (wet AMD), diabetic retinopathy (DR), and retinal vein occlusion (RVO). These emerging technologies aim to deliver therapeutic agents for significantly extended durations, potentially years or even a lifetime, from a single administration (e.g., via subretinal or suprachoroidal injection of a viral vector). This could fundamentally disrupt the market for repeated intravitreal injections and less long-acting sustained-release implants, including EyePoint's Durasert-based pipeline candidates like EYP-1901.
AI Generated Analysis | Feedback
EyePoint Pharmaceuticals (NASDAQ: EYPT) is focused on developing and commercializing innovative ophthalmic products, primarily utilizing sustained-release drug delivery technologies for serious retinal diseases. The company's pipeline product, EYP-1901, also known as DURAVYU, is being developed to treat wet age-related macular degeneration (Wet AMD) and diabetic macular edema (DME).
The combined global addressable market for wet AMD and DME is estimated to be approximately $10 billion and is currently growing. This market represents a significant portion of the global branded retinal disease market.
While EyePoint Pharmaceuticals has marketed products such as YUTIQ® for chronic non-infectious uveitis and DEXYCU® for postoperative inflammation following cataract surgery, the company's strategic focus and future growth are increasingly centered on its pipeline, particularly DURAVYU.
AI Generated Analysis | Feedback
EyePoint Pharmaceuticals (NASDAQ: EYPT) anticipates several key drivers for future revenue growth over the next 2-3 years, primarily centered around its lead product candidate, DURAVYU (vorolanib intravitreal insert), and its proprietary Durasert E™ technology.
-
Approval and Commercialization of DURAVYU for Wet Age-Related Macular Degeneration (AMD): EyePoint is actively progressing its Phase 3 pivotal trials, LUGANO and LUCIA, for DURAVYU in wet AMD. Enrollment in these trials has exceeded expectations, with topline data anticipated in mid-2026. Successful trial outcomes and subsequent regulatory approval would allow EyePoint to enter a significant market with a potentially differentiated treatment option.
-
Approval and Commercialization of DURAVYU for Diabetic Macular Edema (DME): Building on positive Phase 2 VERONA trial data, EyePoint plans to initiate Phase 3 trials (COMO and CAPRI) for DURAVYU in DME, with the first patient dosing expected in Q1 2026. This represents another substantial market opportunity for the company.
-
DURAVYU's Differentiated Profile and Sustained-Release Technology: DURAVYU leverages EyePoint's proprietary bioerodible Durasert E™ technology for sustained intraocular drug delivery, offering the potential for a long-acting maintenance therapy. The drug also exhibits a multi-mechanism of action, inhibiting VEGF-mediated vascular permeability and IL-6 mediated inflammation. This differentiated profile, aiming to reduce treatment burden and potentially improve patient outcomes, is expected to drive market adoption upon approval.
-
Expansion of Pipeline utilizing Durasert E™ Technology: Beyond the immediate focus on DURAVYU for wet AMD and DME, EyePoint's proprietary Durasert E™ technology serves as a platform for developing additional innovative therapeutics for serious retinal diseases. The company's strategic focus on pipeline growth and expansion, by leveraging this proven technology, indicates potential for future revenue streams from new product candidates.
AI Generated Analysis | Feedback
Share Issuance
- EyePoint Pharmaceuticals announced an underwritten public offering of $150 million of common stock in October 2025, with an option for underwriters to purchase an additional $22.5 million, with gross proceeds expected to be approximately $150 million.
- In November 2025, the company filed a prospectus supplement for a registered offering of up to $200 million in common stock under a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co., dated August 5, 2020.
- In October 2024, EyePoint completed an underwritten public offering of 14,636,363 shares of common stock at $11.00 per share, which included the full exercise of the underwriters' option to purchase an additional 1,909,090 shares.
Inbound Investments
- In January 2021, Ocumension Therapeutics made a $15.7 million equity investment in EyePoint Pharmaceuticals, purchasing approximately 3.01 million shares of common stock.
- This $15.7 million Post IPO funding round on January 3, 2021, with Ocumension as a participant, was EyePoint Pharmaceuticals' latest funding round.
Capital Expenditures
- EyePoint Pharmaceuticals reported capital expenditures of approximately -$4.05 million in 2020, -$3.48 million in 2021, -$2.15 million in 2022, -$156,000 in 2023, and -$362,000 in 2024.
